Natera/$NTRA
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Natera
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.
- Ticker
- $NTRA
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 6,138
- Headquarters
- Austin, United States
- Website
- www.natera.com
Natera Metrics
BasicAdvanced
$63B
-
-$1.37
1.51
-
Price and volume
Market cap
$63B
Beta
1.51
52-week high
$437.41
52-week low
$181.00
Average daily volume
1.7M
Financial strength
Current ratio
2.999
Quick ratio
2.736
Long term debt to equity
0.079
Total debt to equity
0.123
Interest coverage (TTM)
-75.89%
Profitability
EBITDA (TTM)
-224.421
Gross margin (TTM)
65.23%
Net profit margin (TTM)
-7.11%
Operating margin (TTM)
-10.54%
Effective tax rate (TTM)
23.88%
Revenue per employee (TTM)
$440,000
Management effectiveness
Return on assets (TTM)
-8.08%
Return on equity (TTM)
-12.54%
Valuation
Price to revenue (TTM)
22.565
Price to book
34.38
Price to tangible book (TTM)
47.43
Price to free cash flow (TTM)
1,193.131
Free cash flow yield (TTM)
0.08%
Free cash flow per share (TTM)
0.365
Growth
Revenue change (TTM)
37.82%
Earnings per share change (TTM)
-28.65%
3-year revenue growth (CAGR)
42.73%
10-year revenue growth (CAGR)
29.03%
3-year earnings per share growth (CAGR)
-34.10%
10-year earnings per share growth (CAGR)
-0.78%
What the Analysts think about Natera
Analyst ratings (Buy, Hold, Sell) for Natera stock.
Analyst projections of the future price of Natera stock.
Bulls say / Bears say
Second-quarter revenue rose 37.7% year on year, with tests processed up 22.4%, and Natera raised its 2026 revenue outlook by $100 million at the midpoint. This suggests strong demand and continued scaling across its testing business. (Natera)
Signatera is gaining clinical and regulatory traction: it received approvals in Japan and the EU, and new ESMO data reported that its results influenced treatment plans in a phase III colon cancer study. Wider adoption could strengthen Natera’s oncology growth and reimbursement prospects. (Natera, Natera)
Medicare expanded coverage for Prospera transplant monitoring, including more tests in the first years after transplant. Broader reimbursement could support higher test volumes and revenue from Natera’s organ-health business. (Natera, Investing.com)
Natera remains loss-making despite rapid growth: it reported a $67 million net loss in the second quarter, while operating expenses rose 21.5% year on year. Heavy investment means revenue growth has yet to translate into sustained profits. (Natera)
A material share of reported revenue still depends on estimates for tests delivered in earlier periods: first-half 2026 adjustments added $113.3 million. If reimbursement collections or estimates disappoint, reported revenue and margins could be weaker than headline growth suggests. (SEC)
Legal and regulatory exposure remains hard to quantify: Natera disclosed ongoing government inquiries and other proceedings, with $33.2 million accrued for probable, estimable legal contingencies and no reliable estimate of additional possible losses. Unfavourable outcomes could bring further costs or disrupt its business. (SEC, Reuters)
Data summarised monthly by Lightyear AI. Last updated on 29 Oct 2026.
Natera Financial Performance
Revenues and expenses
Natera Earnings Performance
Company profitability
Upcoming events
No upcoming events
Natera News
AllArticlesVideos
Natera, Shake Shack, eBay And More On CNBC's ‘Final Trades'
Benzinga7 hours ago
Signatera™ Genome with Phased and Structural Variants Highlighted in ESMO Presidential Symposium, Supporting the Critical Role of MRD-Guided Treatment in Bladder Cancer
Business Wire3 days ago
Natera Shares Real-World Analyses and Data at ASN Kidney Week 2026, Highlighting the Critical Need for Genetic Testing with Renasight™
Business Wire4 days ago
Funds containing Natera
AllUSDEURGBP
Fund name | Fund size | $NTRA weighting |
|---|---|---|
iShares Healthcare Innovation£DRDR | $1.3B | 2.20% |
iShares Healthcare Innovation€2B78 | $1.2B | 2.20% |
iShares Healthcare Innovation$HEAL | $1.3B | 2.20% |
iShares AI Adopters and Applications£AIAA | $188M | 1.14% |
iShares AI Adopters and Applications€AIAA | $188M | 1.14% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.